# A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia

> **NCT06113289** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** ASTX727
- **DRUG:** ASTX029-01

## Key facts

- **NCT ID:** NCT06113289
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-02-08
- **Primary completion:** 2025-03-06
- **Final completion:** 2025-03-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI Request
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113289, "A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06113289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*